Corporate Banner
Satellite Banner
Proteomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Qlucore Receives European Funding That will Benefit Personalized Medicine

Published: Thursday, September 05, 2013
Last Updated: Thursday, September 05, 2013
Bookmark and Share
Hepatitis C patients to benefit from European funding awarded to Qlucore.

Qlucore has been awarded funding of €0.6 million over a three year period by the European Commission's 7th Framework Programme as part of a €6.0 million consortium project (Grant n° 601851) for the development of mathematical and statistical algorithms focusing on integrating data from multiple analytical platforms focusing on integrating genetic and proteomic data with clinical variables.

On receiving the award, Carl-Johan Ivarsson, CEO, Qlucore said, "Personalized medicine, and in particular Hepatitis C patients, will benefit from the project outcome. One of the primary objectives of the consortium is to provide predictive tests that will lead to improvements in the health of these patients, which will simultaneously reduce the costs of medical treatment."

The consortium, known as the PoC-HCV consortium, aims to develop integrated genetic and protein biomarker tests for use in treating and monitoring HCV patients, as well as in clinical research.

Data and algorithms will be tailored for analysis and treatment in a Point of Care environment for Hepatitis C. One of the outputs from the consortium will be a mobile application prototype where the algorithms are implemented.

Establishing a path for validation and implementation of point-of-care medical devices is a challenge, and the driving vision of the Consortium.

The consortium additionally consists of the coordinator Inserm (Institut Pasteur) (France), Inserm Transfert (France), Epistem (UK) and Biosurfit (Portugal).

With the primary objective to provide Point of Care diagnostic and predictive tests and reduce costs, the approach will capitalize on the consortium's combined expertise spanning leading edge miniaturized molecular testing, lab-on-a-chip systems and algorithm design.

These enabling technologies will permit the development and delivery of the first integrated genetic and protein biomarker tests, applied here to Hepatitis C disease for: (i) making the decision to treat; (ii) selection of therapy; (iii) response-guided monitoring; and (iv) clinical research practices.

Hepatatis-C is a global public health problem with over 150 million people infected worldwide, representing a 15 billion Euro/year market. It is particularly prevalent in under-developed countries and treatments can be very costly.

One vision is to allow the physicians to make better treatment decisions (selecting the correct drug) and hence lower the total cost of treatment. In countries with many infected patients and limited healthcare budget this will provide an enormous improvement in quality of life for this patient group.

The algorithms developed by Qlucore will be based on classification techniques. They will also be available in future versions of Qlucore Omics Explorer and hence enable researchers and physicians in other areas to benefit from the results.

Qlucore has recruited and increased its engineering capacity in order to fulfil its role in the PoC HCV consortium. This, combined with the recently announced grant to Qlucore from VINNOVA (Swedish Governmental Agency for Innovation Systems) is additional validation of the high value being placed on developments currently being undertaken by Qlucore.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Qlucore, Nebion Collaborate
Partnership aims to address complementary use cases.
Friday, February 07, 2014
Using Qlucore Omics Explorer for Interpreting Leukemia Proteomics Data
Qlucore software has speeded up the process and enabled discovery for leukemia researcher Steven Kornblau.
Monday, November 18, 2013
Visualising Complex Data Results from 100,000 Cancer Patients
For decades, biomedical scientists have tried to develop a diagnostic tool for the early stages of cancer.
Wednesday, December 12, 2012
New Biomarkers Could Offer Vital Clues for Cancer Research
European funding for cancer research has led to some interesting results in recent years, says Carl-Johan Ivarsson, CEO at Qlucore.
Friday, May 04, 2012
Scientific News
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Lemon Juice and Human Norovirus
Citric acid may prevent the highly contagious norovirus from infecting humans, scientists discovered from the German Cancer Research Center.
Signature of Microbiomes Linked to Schizophrenia
Studying microbiomes in throat may help identify causes and treatments of brain disorder.
Structural Discoveries Could Aid in Better Drug Design
Scientists have uncovered the structural details of how some proteins interact to turn two different signals into a single integrated output.
Protein Found to Play a Key Role in Blocking Pathogen Survival
Calprotectin fends off microbial invaders by limiting access to iron, an important nutrient.
Study Identifies the Off Switch for Biofilm Formation
New discovery could help prevent the formation of infectious bacterial films on hospital equipment.
How DNA ‘Proofreader’ Proteins Pick and Edit Their Reading Material
Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have discovered how two important proofreader proteins know where to look for errors during DNA replication and how they work together to signal the body’s repair mechanism.
Protein Found to Control Inflammatory Response
A new Northwestern Medicine study shows that a protein called POP1 prevents severe inflammation and, potentially, diseases caused by excessive inflammatory responses.
X-ray Laser Experiment Could Help in Designing Drugs for Brain Disorders
Scientists found that when two protein structures in the brain join up, they act as an amplifier for a slight increase in calcium concentration, triggering a gunshot-like release of neurotransmitters from one neuron to another.
Team Identifies Structure of Tumor-Suppressing Protein
An international group of researchers led by Carnegie Mellon University physicists Mathias Lösche and Frank Heinrich have established the structure of an important tumor suppressing protein, PTEN.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!